Company intelligence / Profile preview

Seyltx, Inc.

Cambridge, Massachusetts, United Statesseyltx.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Seyltx has acquired ifenprodil from Algernon Pharmaceuticals, which has successfully completed a Phase 2a trial in cough associated with IPF. Pre-clinical dose-ranging data showed near-complete suppression of refractory chronic cough within the therapeutic index. The company is planning a Phase 2b program called SILINDA (Selective Ifenprodil INhibition of NMDA), with the first patient expected to be enrolled in early 2025[2][4].

Therapeutic areas: PulmonologyNeurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

ifenprodil

Partnerships

Algernon Pharmaceuticals

Beyond the preview

Go deeper on Seyltx, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Seyltx, Inc..